ReviewSeminars in liver disease2019
The Contribution of B Cells in Autoimmune Liver Diseases.
Review in Seminars in liver disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 59 citations in OpenAlex.
- Immune cell remodelling and the peribiliary immune niche in primary biliary cholangitis: from initiation to chronicity.eGastroenterology · 2026Review
- Article
- Research progress and perspectives of non-coding RNAs in primary biliary cholangitis: from mechanisms to therapeutics.Frontiers in medicine · 2025Review
- Correlation of the Expression Profile of Peripheral Leukocyte and Liver Tissue Immune Markers With Serum Liver Injury Indices in Children With Biliary Atresia.Mediators of inflammation · 2025Article
- Role of immune cell interactions in alcohol-associated liver diseases.Liver research (Beijing, China) · 2024Review
- Gut microbiota trigger host liver immune responses that affect drug-metabolising enzymes.Frontiers in immunology · 2024Review
- Single cell RNA-sequencing analysis reveals thatJHEP reports : innovation in hepatology · 2023Article
- Seronegative autoimmune hepatitis in childhood.World journal of clinical pediatrics · 2023Review
- Seronegative Autoimmune Hepatitis.Journal of clinical and translational hepatology · 2023Review
- Innate immunity and early liver inflammation.Frontiers in immunology · 2023Review
- Article
- Mechanism-based target therapy in primary biliary cholangitis: opportunities before liver cirrhosis?Frontiers in immunology · 2023Review
- TOPAS, a network-based approach to detect disease modules in a top-down fashion.NAR genomics and bioinformatics · 2022Article
- Role of B Lymphocytes in the Pathogenesis of NAFLD: A 2022 Update.International journal of molecular sciences · 2022Review
- Natural history and management of refractory autoimmune hepatitis.Clinical liver disease · 2022Review
- Expression of HLA and Autoimmune Pathway Genes in Liver Biopsies of Young Subjects With Autoimmune Hepatitis Type 1.Journal of pediatric gastroenterology and nutrition · 2022Article
- Mesenchymal stem cells-based therapy in liver diseases.Molecular biomedicine · 2022Review
- B cells in autoimmune hepatitis: bystanders or central players?Seminars in immunopathology · 2022Review
- Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study.Diagnostics (Basel, Switzerland) · 2022Article
- Antidepressants cheer up hepatic B1 B cells: Hope for the treatment of autoimmune liver diseases?Frontiers in immunology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Autoreactive B cells can promote autoimmunity through antigen presentation to autoreactive T cells, production of autoantibodies, generation of cytokines promoting T cell activation and differentiation, and inhibition of regulatory T cells and B cells. Here, the authors highlight studies pertaining to B cell mechanisms associated with disease pathogenesis and outcomes in autoimmune hepatitis and the immune-mediated cholangiopathies (primary biliary cholangitis, primary sclerosing cholangitis, and biliary atresia). The vast majority of investigations focus on autoantibodies and future research endeavors should include deciphering the role of the B cell in T cell activation (through antigen presentation, cytokine/chemokine production, and inhibition of regulation). Targeting B cell mechanisms in the treatment of autoimmune liver diseases is also highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.